Who Paid My Doc
Aung Naing
Internal Medicine Houston, TX Medical Doctor
NPI 1104837590 CMS profile 366226
1515 Holcombe Blvd, Houston, TX 77030
General payments
$20,444
Research payments
$6,991
Ownership & investment interest
$0
Research they led as principal investigator
$30,537,327
Through program year 2025, Aung Naing of Houston, TX is reported in the CMS Open Payments database as having received $20,444 across 27 general payments and $6,991 in research payments paid to them. Separately, studies naming them as principal investigator received $30,537,327 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,704 | 5 | |
| 2024 | Research | $4,531 | 4 | |
| 2023 | General | $3,375 | 2 | |
| 2022 | General | $5,205 | 2 | |
| 2021 | General | $2,639 | 1 | |
| 2020 | General | $211 | 1 | |
| 2020 | Research | $2,460 | 4 | |
| 2019 | General | $4,309 | 16 |
Beside peers
- Aung Naing
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Aung Naing were reported at $4,704. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Aung Naing | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,309 | $159 | $48–$570 | $163 |
| 2020 | $211 | $119 | $33–$402 | $114 |
| 2021 | $2,639 | $135 | $37–$521 | $132 |
| 2022 | $5,205 | $141 | $42–$496 | $149 |
| 2023 | $3,375 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $4,704 | $156 | $47–$551 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$50,460
Medicare patients
192
Services billed
483
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 64% | |
| Arthritis | 35% | |
| Diabetes | 33% | |
| Depression | 28% | |
| Ischemic heart disease | 20% | |
| Chronic kidney disease | 20% | |
| Osteoporosis | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
35 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Texas
Related records
Internal Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.